Skip to main content

Topical Thrombin

Topical thrombin is a purified active coagulation factor that converts local fibrinogen to fibrin at a bleeding surface; it bypasses upstream coagulation steps but still requires fibrinogen for clot formation.[2] Available in bovine, pooled-human plasma-derived, and recombinant human sources, topical thrombin is used alone (spray or painted onto a surface), combined with gelatin matrix (Gelfoam and thrombin slurry, or pre-formulated FloSeal), or as a component of fibrin sealants (Tisseel, Evicel).[1]

Sources​

SourceProduct namesNotes
BovineThrombin-JMIBoxed warning: fatal severe bleeding or thrombosis from antibodies to bovine thrombin or factor V; no re-exposure if antibodies known or suspected[3]
Human plasma pooledEvithromDerived from screened human plasma; infectious-agent transmission remains possible despite risk-reduction steps (CJD transmission is theoretical); contraindicated after anaphylaxis or another severe systemic reaction to Evithrom or human blood products[4]
Recombinant humanRecothromRecombinant CHO-cell production; not human-plasma-derived; hamster/component allergy precautions apply

Recothrom avoids a human plasma donor supply, but it is produced in a modified hamster-cell line and may contain hamster or snake proteins. Check the local formulary and product-specific allergy precautions.[2] In a mixed-surgery trial with baseline and day-29 samples, 3/198 (1.5%) Recothrom recipients developed specific anti-product antibodies, while 43/200 (21.5%) bovine-thrombin recipients were antibody-positive after treatment.[2] None of the anti-Recothrom antibodies neutralized native human thrombin; the bovine-product antibodies were not tested for this endpoint.[2][3][5]

Mechanism​

  • Thrombin cleaves fibrinogen directly to fibrin monomer, which polymerizes into insoluble fibrin strands
  • Bypasses the entire intrinsic and extrinsic cascade and may assist local hemostasis despite some upstream factor deficiencies, but requires fibrinogen and is not systemic anticoagulant reversal
  • Concentration is product-specific. Recothrom and Evithrom are reconstituted to 1,000 units/mL.[2][4] Thrombin-JMI is labeled at 1,000–2,000 IU/mL (or dry powder on oozing surfaces), with about 100 IU/mL used for plastic surgery and skin grafting[2][3][4]
  • In mixed-specialty trials using gelatin sponge, hemostasis at one selected bleeding site by 10 minutes occurred in 95% of both recombinant (N=198) and bovine (N=203) efficacy-evaluable groups, and in 149/153 (97.4%) human versus 148/152 (97.4%) bovine recipients in a separate trial.[5][6] At 3 minutes in the latter trial, rates were 112/153 (73.2%) and 110/152 (72.4%).[6]

Delivery Modes​

1. Thrombin alone (spray or painted)​

  • Spray applicator or saturated pledget
  • Painted onto a bleeding surface with a blunt catheter or syringe
  • Standalone application. Recothrom may be sprayed onto an accessible bleeding surface or applied with an absorbable gelatin sponge.[2]

2. Thrombin-soaked Gelfoam​

The classical combination:

  • Reconstitute per the product label: Recothrom and Evithrom to 1,000 units/mL[2][4]; Thrombin-JMI routinely to 1,000–2,000 IU/mL[3]
  • Saturate a Gelfoam sponge in the thrombin solution, kneading out air; Evithrom clinical studies used up to 10 mL with an absorbable gelatin sponge[4]
  • Apply the soaked sponge to the visible bleeding surface and hold it with moderate pressure until hemostasis. Moisten the overlying pledget or gauze with sterile saline before lifting it, and remove excess Gelfoam.[7]
  • Provides the mechanical tamponade of Gelfoam and the active biochemistry of thrombin
  • Do not add topical thrombin to oxidized regenerated cellulose (Surgicel): its low pH destroys thrombin activity.[8]

3. Gelatin–thrombin matrix (FloSeal)​

  • See FloSeal
  • Reconstitute the kit's thrombin and mix it with gelatin granules before applying the flowable matrix.[1]

4. Fibrin sealant component​

  • See Fibrin sealants (Tisseel, Evicel)
  • Fibrinogen and thrombin are delivered together by a dual-syringe applicator, forming fibrin at the application site. Tisseel may be dripped or sprayed with an approved device and requires at least 2 minutes for sufficient polymerization; its label warns of potentially fatal gas embolism with improper pressurized spraying.[12] It contains aprotinin and is contraindicated in patients with known aprotinin hypersensitivity.[12]

GU Applications​

  • Nerve-sparing RARP. In a 2005 feasibility series of 17 men, investigators temporarily clamped 27 prostatic vascular pedicles, dissected the neurovascular bundles, then applied FloSeal and dry Gelfoam before releasing the clamps; arterial bleeding required sutures at 4/27 pedicles (15%), and potency follow-up was pending.[13] The current RECOTHROM-containing FloSeal IFU contraindicates application while a vessel is clamped and reports erectile dysfunction after FloSeal use in radical prostatectomy procedures involving cavernous nerves.[10]
  • Partial nephrectomy renal bed. Thrombin-soaked Gelfoam or FloSeal may be used for persistent accessible surface oozing when conventional methods are ineffective or impractical.[2][10] FloSeal contains bovine gelatin and is contraindicated in known bovine-material allergy; it must not be applied without active blood flow, including while the target vessel is clamped or bypassed.[10] In urological procedures, the FloSeal IFU advises against leaving matrix in the renal pelvis or ureters because it may become a focus for calculus formation.[10] A 2026 systematic review found no demonstrated reduction in transfusion, hemorrhagic complications, or urinary leakage from routine hemostat addition to renorrhaphy; agent-specific and rescue effects could not be assessed.[11]
  • Post-prostatectomy pelvic sidewall. Thrombin-soaked pledgets for diffuse oozing
  • Bladder neck reconstruction. After Y-V plasty or complex repair
  • Bone bleeding (pubic bone, sacrum). For exposed marrow oozing, apply the minimum amount of thrombin-soaked Gelfoam to the bleeding surface (operative use, not a bone-specific labeled indication); avoid packing or wadding it into a bony cavity and remove excess once hemostasis is achieved because swelling can compress adjacent tissue.[7]

Contraindications and Cautions​

  • Never inject intravascularly. All three labels say topical use only. Entry into the circulation causes extensive intravascular clotting and can be fatal; fatal thrombosis after inadvertent intravenous injection of bovine thrombin has been reported[2][3]
  • Not for brisk arterial bleeding. All three labels contraindicate use for brisk arterial bleeding (RECOTHROM also says massive; THROMBIN-JMI and EVITHROM say severe); thrombin is for oozing from accessible capillaries and small venules when suture, ligature or cautery is ineffective or impractical[2][3][4]
  • Bovine thrombin antibodies. In one mixed-surgery trial, the THROMBIN-JMI label reports 18.4% seroconversion; 43/200 (21.5%) were antibody-positive after treatment.[3] Antibodies to bovine thrombin or factor V (which can cross-react with human factor V) can cause fatal bleeding or thrombosis. Check coagulation studies if unexplained bleeding follows, and do not re-expose. Recombinant or human thrombin reduces this specific concern but does not eliminate hypersensitivity or other adverse events[3][5]
  • Pediatric use. Recothrom is labeled from age 1 month; Thrombin-JMI safety and effectiveness in children are not established[2][3]
  • Anaphylaxis. Possible with any thrombin product. Recothrom is contraindicated with known hamster-protein or component hypersensitivity; Thrombin-JMI with hypersensitivity to bovine material; Evithrom with prior anaphylaxis or another severe systemic reaction to Evithrom or human blood products.[2][3][4] When thrombin is combined with Gelfoam, known porcine-collagen allergy is a separate contraindication; life-threatening anaphylaxis, including death, has been reported after absorbable gelatin exposure.[7]
  • Fibrinogen deficiency. Thrombin needs local fibrinogen to form fibrin. A fibrin sealant supplies fibrinogen at the treated surface but does not correct systemic hypofibrinogenemia; assess a significant systemic deficit separately and consider fibrinogen replacement when indicated.[2][9]

Key Pearl — When to Reach for Thrombin​

Topical thrombin may be an adjunct for oozing (not brisk arterial) bleeding when:

  • In a heparinized patient with accessible oozing despite a passive matrix, topical thrombin may be used as a local adjunct when suture, ligature, or cautery is ineffective or impractical.[2]
  • In a patient with cirrhosis, DIC, factor deficiency, or DOAC exposure, consider topical thrombin for accessible oozing only as a local adjunct when standard hemostasis is ineffective or impractical. Assess and treat the systemic disorder separately; benefit in these specific populations is uncertain.[2][9]
  • Bleeding is from a raw surface that cannot be cauterized (nerve, major vessel adventitia, bone)
  • Gelfoam alone is failing. Saturate it with thrombin to upgrade to an active agent

See Also​

References​

1. Schreiber MA, Neveleff DJ. Achieving hemostasis with topical hemostats: making clinically and economically appropriate decisions in the surgical and trauma settings. AORN J. 2011;94(5):S1–S20. doi:10.1016/j.aorn.2011.09.018

2. RECOTHROM prescribing information. DailyMed, revised June 2025; topical-only administration and hamster/component hypersensitivity precautions.

3. THROMBIN-JMI (thrombin, topical, bovine) prescribing information. Pfizer, DailyMed, September 2026; boxed warning, contraindications, reconstitution (1,000–2,000 IU/mL).

4. EVITHROM (thrombin, topical, human) prescribing information. Ethicon, DailyMed; 1,000 units/mL after reconstitution, contraindications, infectious-agent risk.

5. Chapman WC, Singla N, Genyk Y, et al. A phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis. J Am Coll Surg. 2007;205(2):256-65. doi:10.1016/j.jamcollsurg.2007.03.020

6. Doria C, Fischer CP, Wood CG, et al. Phase 3, randomized, double-blind study of plasma-derived human thrombin versus bovine thrombin in achieving hemostasis in patients undergoing surgery. Curr Med Res Opin. 2008;24(3):785-94. doi:10.1185/030079908X273426

7. GELFOAM Sterile Sponge instructions for use. Pfizer, revised July 2024; wet application with thrombin, minimum quantity, and bony-cavity packing warnings.

8. SURGICEL Absorbable Hemostat essential product information. Ethicon, November 2021; low-pH incompatibility with added thrombin.

9. Coccolini F, Shander A, Ceresoli M, et al. Strategies to prevent blood loss and reduce transfusion in emergency general surgery, WSES-AAST consensus paper. World J Emerg Surg. 2024;19:26. doi:10.1186/s13017-024-00554-7

10. Baxter Healthcare Corporation. FLOSEAL Hemostatic Matrix, 5 mL: instructions for use. Product labeling; accessed October 2026.

11. da Cruz JAS, de Souza Almeida A, Terada BD, et al. "Adjunctive topical hemostatic agents combined with renorrhaphy versus renorrhaphy alone during partial nephrectomy: a systematic review and meta-analysis." World J Urol. 2026;44(1):592. doi:10.1007/s00345-026-06679-5

12. Baxter Healthcare Corporation. TISSEEL Fibrin Sealant prescribing information. DailyMed; revised September 2025.

13. Ahlering TE, Eichel L, Chou D, Skarecky DW. "Feasibility study for robotic radical prostatectomy cautery-free neurovascular bundle preservation." Urology. 2005;65(5):994-997. doi:10.1016/j.urology.2004.11.023